Burden of skeletal-related events in prostate cancer: unmet need in pain improvement

被引:47
作者
Broder, M. S. [1 ]
Gutierrez, B. [2 ]
Cherepanov, D. [1 ]
Linhares, Y. [3 ]
机构
[1] Partnership Hlth Analyt Res LLC, Beverly Hills, CA 90212 USA
[2] Otsuka Amer Pharmaceut Inc, Princeton, NJ 08540 USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
关键词
Prostatic neoplasms; Bone neoplasms; Fractures; Bone; Spinal cord compression; Radiotherapy; Pain; prostate cancer; metastatic bone disease; bone metastases; skeletal-related events; QUALITY-OF-LIFE; METASTATIC BONE-DISEASE; SPINAL-CORD COMPRESSION; RANDOMIZED PHASE-II; ZOLEDRONIC ACID; PALLIATIVE TREATMENT; SURVIVAL; TRIAL; RADIOTHERAPY; CARCINOMA;
D O I
10.1007/s00520-014-2437-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Up to 75 % of patients with prostate cancer experience metastatic bone disease, which leads to an increased risk for skeletal-related events (SREs) including pathological bone fracture, spinal cord compression, and hypercalcemia of malignancy. Our objective was to systematically review the literature on the impact of SREs on quality of life (QOL), morbidity, and survival with a primary focus on the impact of SREs on pain in prostate cancer patients. We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on the US Food and Drug Administration and European Medicines Agency definition of an SRE, which includes pathologic fracture, spinal cord compression (SCC), hypercalcemia of malignancy, and radiotherapy or surgery to bone resulting from severe bone pain. A total of 209 articles were screened, of which 173 were excluded, and 36 were included in this review. Patients with SREs had more pain and worse survival compared with no SREs. Pathologic bone fractures worsened QOL and were associated with shorter survival. Radiation therapy of SCC alleviated pain and improved morbidity. SCC was associated with decreases in patient survival. Radiation therapy and surgery to bone improved pain. Specific SREs are associated with worse outcomes, including increased pain, poorer QOL, morbidity, and survival. Treatment of SREs is associated with improved pain, although there remains a need for more effective treatment of SREs in prostate cancer patients.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 54 条
  • [41] Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer
    Sartor, O
    Reid, RH
    Hoskin, PJ
    Quick, DP
    Ell, PJ
    Coleman, RE
    Kotler, JA
    Freeman, LM
    Olivier, P
    [J]. UROLOGY, 2004, 63 (05) : 940 - 945
  • [42] Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain
    Sartor, Oliver
    Reid, Robert H.
    Bushnell, David L.
    Quick, Donald P.
    Ell, Peter J.
    [J]. CANCER, 2007, 109 (03) : 637 - 643
  • [43] Sze WM, 2008, COCHRANE DB SYST REV, V2, P1
  • [44] Tangen Catherine M, 2003, Clin Prostate Cancer, V2, P41, DOI 10.3816/CGC.2003.n.011
  • [45] The Role of Bone-Seeking Radionuclides in the Palliative Treatment of Patients With Painful Osteoblastic Skeletal Metastases
    Tomblyn, Michael
    [J]. CANCER CONTROL, 2012, 19 (02) : 137 - 144
  • [46] Tripathi M, 2006, Indian J Cancer, V43, P86
  • [47] Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
    Turner, SL
    Gruenewald, S
    Spry, N
    Gebski, V
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (03) : 297 - 302
  • [48] US Food and Drug Administration, 2004, FDA PUBL WORKSH CLIN
  • [49] Prediction of survival in patients with metastases in the spinal column - Results based on a randomized trial of radiotherapy
    van der Linden, YM
    Dijkstra, SPDS
    Vonk, EJA
    Marijnen, CAM
    Leer, JWH
    [J]. CANCER, 2005, 103 (02) : 320 - 328
  • [50] Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
    Vogel, CL
    Yanagihara, RH
    Wood, AJ
    Schnell, FM
    Henderson, C
    Kaplan, BH
    Purdy, MH
    Orlowski, R
    Decker, JL
    Lacerna, L
    Hohneker, JA
    [J]. ONCOLOGIST, 2004, 9 (06) : 687 - 695